Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 40411813SCH2001 | Other Identifier | Janssen Research & Development, LLC | |
| 2010-023369-23 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.
This is a first-in-human study of JNJ-40411813 in schizophrenic patients who are not currently receiving antipsychotic drug treatment (referred to as "(sub) acute" patients) and in patients who are currently taking antipsychotic drug treatment (referred to as "stable" patients). The study will consist of 2 parts: Part A and Part B. Part A will be open-label (patients will know the identity of study treatment), and (sub)acute schizophrenic patients will receive monotherapy (treatment with one drug) with JNJ-40411813. Part B will be double-blind (patient and study staff will not know the identity of study treatment) and will randomize (assign by chance) patients with stable but symptomatic schizophrenia to receive treatment with JNJ-40411813 or a placebo (treatment identical in appearance to JNJ-40411813 but does not contain active drug) as add-on therapy to their currently prescribed antipsychotic medication. Parts A (JNJ-40411813 monotherapy) and B (JNJ-40411813 add-on therapy) will run simultaneously. Patients will take JNJ-40411813 and placebo capsules orally (by mouth) twice daily (bid) with a meal. Part A: Patients will take JNJ-40411813 50 mg (1 capsule) bid up to 150 mg (3 capsules) bid for up to 12 weeks. Part B: Patients will take JNJ-40411813 50 mg bid or placebo bid for 4 weeks. After 4 weeks, the dose of JNJ-40411813 may be increased up to 150 mg bid for 6 weeks, and patients assigned to placebo may take JNJ-40411813 50 mg bid to 150 mg bid for up to 10 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JNJ-40411813 (Part A) | Experimental | JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks. |
|
| JNJ-40411813 (Part B) | Experimental | JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks. |
|
| Placebo and JNJ-40411813 (Part B) | Experimental | Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JNJ-40411813 | Drug | JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Udvalg for Klinische Undersogelser (UKU) ratings for side effects reported by patients | Up to 12 weeks | |
| The number of patients with abnormal results from clinical laboratory tests performed as a measure of safety and tolerability | Up to 12 weeks | |
| The number of patients with abnormal results from electrocardiograms (ECGs) performed as a measure of safety and tolerability | Up to 12 weeks | |
| The number of patients with abnormal results from physical examinations (including vital signs measurements) performed as a measure of safety and tolerability | Up to 12 weeks | |
| Number of patients with adverse events reported as a measure of safety and tolerability | Up to 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Positive and Negative Syndrome Scale (PANSS) scores to explore potential therapeutic effect of study drug | Up to 12 weeks | |
| Clinical Global Impression - Schizophrenia (CGI-SCH) ratings to explore potential therapeutic effect of study drug | Up to 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC C. Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Innsbruck | Austria | |||||
Not provided
Not provided
Not provided
Not provided
Not provided
| JNJ-40411813 | Drug | JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks. |
|
| Placebo | Drug | Placebo capsule (s) orally twice daily with a meal for 4 weeks. |
|
| Antipsychotic medication | Drug | Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B. |
|
| Subjective Well-being under Neuroleptics Scale (SWN) scores to explore potential therapeutic effect of study drug | Up to 12 weeks |
| Plasma (blood) concentration of JNJ-40411813 | Up to 12 weeks |
| Salzburg |
| Austria |
| Vienna | Austria |
| Dave | Belgium |
| Duffel | Belgium |
| Kortenberg | Belgium |
| Lede | Belgium |
| Plovdiv | Bulgaria |
| Radnevo | Bulgaria |
| Berlin | Germany |
| Hamburg | Germany |
| Mainz | Germany |
| Mannheim | Germany |
| München | Germany |
| Arad | Romania |
| Brasov | Romania |
| Iași | Romania |
| Sibiu | Romania |
| Barcelona | Spain |
| Zamora | Spain |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000594993 | 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone |
| D014150 | Antipsychotic Agents |
| ID | Term |
|---|---|
| D014149 | Tranquilizing Agents |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |
| D011619 | Psychotropic Drugs |
Not provided
Not provided